| scholarly article | Q13442814 |
| P2093 | author name string | Ryo Takata | |
| Hiroko Iijima | |||
| Takashi Nishimura | |||
| Nobuhiro Aizawa | |||
| Shuhei Nishiguchi | |||
| Yoshiyuki Sakai | |||
| Hirayuki Enomoto | |||
| Hiroki Nishikawa | |||
| Kazunori Yoh | |||
| Kunihiro Hasegawa | |||
| Kyohei Kishino | |||
| Naoto Ikeda | |||
| Tomoyuki Takashima | |||
| Yoshihiro Shimono | |||
| Yoshinori Iwata | |||
| Noriko Ishii | |||
| Yukihisa Yuri | |||
| P2860 | cites work | The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme | Q27480807 |
| Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy | Q33767530 | ||
| Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review | Q34073347 | ||
| National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. | Q34156940 | ||
| Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
| Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review | Q35037545 | ||
| Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade | Q35065472 | ||
| Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus | Q36650834 | ||
| Zinc and the liver: an active interaction | Q36784421 | ||
| A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy | Q36945543 | ||
| Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade | Q37174913 | ||
| Can zinc enhance response interferon therapy for patients with HCV-related liver disease? | Q38025376 | ||
| Role of Nutrition and Muscle in Cirrhosis | Q38792500 | ||
| Evidence-based clinical practice guidelines for liver cirrhosis 2015. | Q38849427 | ||
| Treatment of Patients with Cirrhosis | Q38936166 | ||
| A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. | Q39743925 | ||
| The NS5A protein of hepatitis C virus is a zinc metalloprotein | Q40520544 | ||
| Quantitative fibrosis estimation by image analysis predicts development of decompensation, composite events and defines event-free survival in chronic hepatitis B patients. | Q40749734 | ||
| Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma | Q40838161 | ||
| Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma | Q41066315 | ||
| Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Q41962614 | ||
| Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan | Q43161784 | ||
| Kinetic analysis of zinc metabolism and its regulation in normal humans | Q45197132 | ||
| High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study | Q46802343 | ||
| Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. | Q51019611 | ||
| Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. | Q53407925 | ||
| Epidemiology and Elimination of HCV-Related Liver Disease | Q57297223 | ||
| What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection? | Q58118307 | ||
| Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B | Q59360940 | ||
| Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score | Q60303060 | ||
| Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease | Q79264261 | ||
| Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis | Q81313146 | ||
| Liver cirrhosis | Q87200165 | ||
| EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis | Q88353946 | ||
| Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial | Q90387172 | ||
| Zinc and Sepsis | Q90639033 | ||
| Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? | Q91154130 | ||
| Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis | Q91446059 | ||
| Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis | Q91592547 | ||
| Changes in serum zinc levels in hepatitis C patients before and after treatment with direct-acting antiviral agents | Q91952810 | ||
| Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update | Q92125346 | ||
| Serum zinc concentration and quality of life in chronic liver diseases | Q92374973 | ||
| Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis | Q92495016 | ||
| Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C | Q92501596 | ||
| Hypozincemia is associated with human hepatocarcinogenesis in hepatitis C virus-related liver cirrhosis | Q93034814 | ||
| Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial | Q93130458 | ||
| Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial | Q93159674 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | liver cirrhosis | Q147778 |
| Hepatitis C virus | Q708693 | ||
| P577 | publication date | 2020-02-28 | |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis | |
| P478 | volume | 9 |
Search more.